REG - Genflow Biosciences - Recognition of Patentability of Claims

Genflow BiosciencesAnnouncement

20/10/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251020:nRST9236Da&default-theme=true

RNS Number : 9236D  Genflow Biosciences PLC  20 October 2025

 

 

THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO
CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION
(EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN
UNION (WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE PUBLICATION OF THIS
ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS
CONSIDERED TO BE IN THE PUBLIC DOMAIN.

 

Genflow Biosciences Plc

 

European Patent Office 2025 Recognizes the Patentability of Claims of SIRT 6
Variant Patent

 

Genflow Biosciences Plc (LSE:GENF) (OTCQB:GENFF) ("Genflow" or the "Company"),
the only publicly listed longevity company in Europe, is pleased to announce
that its European patent (No. 22808414.1, Publication No. EP4338267) was
officially published in the European Patent Office (EPO) Bulletin on 15
October 2025.

 

The EPO has recognized the patentability of claims of Genflow's Euro-PCT
application, marking a major milestone in the Company's ongoing intellectual
property strategy. The European publication number EP4630038 appeared in the
Bulletin, signifying that the patent application entered its final pre-grant
phase under Article 67(3) EPC. However, Genflow will still need to bring the
description into compliance with the claims to respond to this Official
Letter; only then will the European Patent Office issue the intention to
grant.

 

With publication, provisional protection took effect across participating EPO
member states, allowing Genflow to enforce protection following national
validation. This status confirmed the formal recognition of Genflow's
application and underscored significant progress toward full patent grant and
legal protection across Europe.

 

Strategic Significance

This publication represents a major step toward securing European patent
recognition for key elements of Genflow's longevity gene therapy platform. As
the patent enters its final stage before formal recognition, Genflow is
positioned to benefit from potential EU grant opportunities and stronger
leverage in partnership discussions with pharmaceutical and biotech companies.
It also underscores the continued progress in securing the intellectual
property backbone of Genflow's SIRT6-based technology across Europe.

 

Dr. Eric Leire, Chief Executive Officer of Genflow Biosciences, commented:
"The publication by the EPO represents a major validation of our scientific
innovation and long-term IP strategy. Securing formal European recognition for
our patent moves us closer to full protection of our longevity gene therapy
platform and strengthens our strategic position for future partnerships and
funding opportunities."

 

Contacts

 Genflow Biosciences  Harbor Access
 Dr Eric Leire, CEO   Jonathan Paterson, Investor Relations
 +32-477-495-881      +1 475 477 9401
                      Jonathan.Paterson@Harbor-access.com

 

About Genflow Biosciences

 

Founded in 2020, Genflow Biosciences Plc. (LSE:GENF) (OTCQB:GENFF), a
biotechnology company headquartered in the UK with R&D facilities in
Belgium, is pioneering gene therapies to decelerate the aging process, with
the goal of promoting longer and healthier lives while mitigating the
financial, emotional, and social impacts of a fast-growing aging global
population. Genflow's lead compound, GF-1002, works through the delivery of a
centenarian variant of the SIRT6 gene which has yielded promising results.
Genflow's 12-month proof-of-concept clinical trial evaluating their
SIRT6-centenarian gene therapy in aged dogs began in March 2025. Other
programs planned include a clinical trial that will explore the potential
benefits of GF-1002 in treating MASH (Metabolic Dysfunction-Associated
Steatohepatitis), the most prevalent chronic liver disease for which there are
no effective treatments. Please visit www.genflowbio.com
(http://www.genflowbio.com/)   and follow the Company on LinkedIn
(https://www.linkedin.com/company/genflow-biosciences/?viewAsMember=true)
 and X (https://x.com/genflowbio) .

 

DISCLAIMER

The contents of this announcement have been prepared by, and are the sole
responsibility of, the Company.

This announcement may contain forward-looking statements. The forward-looking
statements include, but are not limited to, statements regarding the Company's
or the Directors' expectations, hopes, beliefs, intentions or strategies
regarding the future. In addition, any statement that refers to projections,
forecasts or other characterisations of future events or circumstances,
including any underlying assumptions, is a forward-looking statement. The
words "anticipate", "believe", "continue", "could", "estimate", "expect",
"intend", "may", "might", "plan", "possible", "potential", "predict",
"project", "seek", "should", "would" and similar expressions, or in each case
their negatives, may identify forward-looking statements, but the absence of
these words does not mean that a statement is not forward-looking.

Forward-looking statements include all matters that are not historical facts.
Forward-looking statements are based on the current expectations and
assumptions regarding the Company, the business, the economy and other future
conditions. Because forward-looking statements relate to the future, by their
nature, they are subject to inherent uncertainties, risks and changes in
circumstances that are difficult to predict. Forward-looking statements are
not guarantees of future performance and the Company's actual financial
condition, actual results of operations and financial performance, and the
development of the industries in which it operates or will operate, may differ
materially from those made in or suggested by the forward-looking statements
contained in this announcement. In addition, even if the Company's financial
condition, results of operations and the development of the industries in
which it operates or will operate, are consistent with the forward-looking
statements contained in this announcement, those results or developments may
not be indicative of financial condition, results of operations or
developments in subsequent periods. Important factors that could cause actual
results to differ materially from those in the forward-looking statements
include regional, national or global, political, economic, social, business,
technological, competitive, market and regulatory conditions.

Any forward-looking statement contained in this announcement applies only as
of the date of this announcement and is expressly qualified in its entirety by
these cautionary statements. Factors or events that could cause the Company's
actual plans or results to differ may emerge from time to time, and it is not
possible for the Company to predict all of them. The Company expressly
disclaims any obligation or undertaking to release publicly any updates or
revisions to any forward-looking statements contained in this announcement to
reflect any change in its expectations or any change in events, conditions or
circumstances on which any forward-looking statement contained in this
announcement is based, unless required to do so by applicable law, the
Prospectus Regulation Rules, the Listing Rules, the Disclosure Guidance and
Transparency Rules of the FCA or the UK Market Abuse Regulation.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCGPGGGUUPAGBM



            Copyright 2019 Regulatory News Service, all rights reserved